Mammogram Facilities, Tumor Biology Linked to the Racial Disparity in Breast Cancer
the Cancer Therapy Advisor take:
Screening facility resources and aggressiveness of tumors were identified as being two major factors that explain racial/ethnic disparity among patients recently screened for symptomatic breast cancer, according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
Participants in this study included patients recently diagnosed with breast cancer and analyzed regarding the probability of symptomatic awareness despite a recent screening mammogram (SADRS). Patients who did not report a recent prior screening were not included in the study analyses.
Results showed SADRS was more common among nH b P=0.0004). Furthermore, an association was identified between SADRS and estrogen and progesterone receptor (ER/PR) negative status and higher grade disease.
SADRS was less likely to be reported at centers with dedicated radiologists and site that were labeled as breast imaging centers of excellence.
Two-thirds of the racial/ethnic disparity in SADRS was explained by tumor biology and facility factors (proportion mediated=70%, P=0.02).
Screening facility resources and aggressiveness of tumors identified as being two major factors that explain racial disparity in breast cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Chemotherapy Plays a Role in Skeletal Muscle Atrophy in Patients With Breast Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Lenalidomide Induces Immunity, Produces Clinical Response in CLL
- Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia